FRISC 1996.

Study characteristics
Methods	Prospective, multicenter double‐blind, randomized, placebo‐controlled, parallel‐group trial
Participants	1506 patients with unstable CAD (unstable angina or non‐Q‐wave myocardial infarction) admitted to hospital with chest pain within the previous 72 hours.
Interventions	2 treatment groups, ASA 300 mg/d (then 75 mg) + one of; Group 1: dalteparin 120 IU/kg SC twice daily x 6 days, then 7500 IU daily for 35‐45 days. Group 2: placebo.
Outcomes	Primary outcome: Difference in the rate of death, new MI during the first 6 days of treatment (acute phase). Secondary outcomes: death and MI after 35‐45 days, revascularization procedures, major/minor bleeding, thrombocytopenia and need for IV heparin (nIVH).
Notes	Acute phase data used for death and MI outcomes.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomization done in blocks
Allocation concealment (selection bias)	Unclear risk	Quote: “Placebo was packaged in matching ampoules and syringes” (identical appearance) but, they don’t describe the method of concealment in sufficient detail (it´s unclear if they were sequentially numbered.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding of participants and personnel likely.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	This study did not address this outcome.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across groups (follow‐up was incomplete in 8 patients [5 dalteparin, 3 placebo]).
Selective reporting (reporting bias)	Low risk	No protocol available, all expected outcomes reported.
Other bias	Low risk